Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.64 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.64 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.64 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.64 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.64 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.64 |
| ▸ | PRNP | P04156 | 2/20 | 0.64 |
| ▸ | MTOR | P42345 | 2/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.64 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.64 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.64 |
| ▸ | NQO2 | P16083 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28644471 | 0.85 | ADRA1D (0.75) | APPCYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL28644469 | 0.85 | ADRA1D (0.75) | APPCYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL4745983 | 0.82 | CHRM2 (0.71) | APPCYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL14424686 | 0.79 | NSD2 (0.54) | APPCYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL21158517 | 0.79 | CHRM2 (0.78) | APPCYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL15481297 | 0.79 | CHRM2 (0.78) | APPCYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL22128051 | 0.79 | USP2 (0.69) | APPCYP2D6CHRM2CHRM4CHRM5 | |
| SCHEMBL15483240 | 0.78 | CHRM2 (0.76) | APPCYP2D6CHRM2CHRM4CHRM5 | |
| (R)-Chloroquine SCHEMBL134500 | 0.78 | CHRM2 (1.00) | APPCYP2D6CHRM2CHRM4CHRM5 | |
| Chloroquine SCHEMBL8934 | 0.78 | CHRM2 (1.00) | APPCYP2D6CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228646-A9 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | AVIDITY BIOSCIENCES INC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-111902148-B | Compositions and methods for treating muscular atrophy and tonic muscular dystrophy | 艾维迪提生物科学公司 | 2024-07-05 | — | — | CN | disclosed |
| CN-118267396-A | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118265544-A | Compositions and methods for treating facial shoulder brachial muscular dystrophy | 艾维迪提生物科学公司 | 2024-06-28 | — | — | CN | disclosed |
| US-12006499-B2 | Una amidites and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | AVIDITY BIOSCIENCES, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240132611-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | Atrium Therapeutics, Inc. | 2024-04-25 | — | — | US | disclosed |
| US-20240132610-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | AVIDITY BIOSCIENCES, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-111655268-B | Nucleic acid-polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2024-03-26 | — | — | CN | disclosed |
| EP-2585113-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA Therapeutics (FR) | 2013-05-01 | — | — | EP | disclosed |
| WO-2012163790-A1 | SPIRO-[1,3]-OXAZINES AND SPIRO-[1,4]-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012163814-A1 | CANCER TREATMENT BY COMBINING DNA MOLECULES MIMICKING DOUBLE STRAND BREAKS WITH HYPERTHERMIA | INSTITUT CURIE (FR) | 2012-12-06 | — | — | WO | disclosed |
| WO-2011161075-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA THERAPEUTICS (FR) | 2011-12-29 | — | — | WO | disclosed |
| WO-2008103409-A2 | COMPOSITIONS OF CHLOROQUINE COUPLED TO ANTIBODIES AND TO OTHER PROTEINS WITH METHODS FOR THEIR SYNTHESIS | KOSAK KEN M | 2008-08-28 | — | — | WO | disclosed |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | KOSAK KENNETH M | 2008-02-28 | — | — | US | disclosed |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | KOSAK KENNETH M | 2007-07-19 | — | — | US | disclosed |
| WO-2007040469-A2 | CHLOROQUINE COUPLED COMPOSITIONS AND METHODS FOR THEIR SYNTHESIS | KOSAK KEN M (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | KOSAK KENNETH M | 2007-03-15 | — | — | US | disclosed |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | KOSAK KENNETH M | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124600-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MYOF, MTPN, PYGM | APP 3618/4885CYP2D6 4806/4885CHRM2 3349/4885 |
| US-20070166281-A1 | Chloroquine coupled antibodies and other proteins with methods for their synthesis | GPR119, CLTA, CHMP4B | APP 2047/4885CYP2D6 3394/4885CHRM2 3747/4885 |
| US-20070060499-A1 | Chloroquine combination drugs and methods for their synthesis | CHMP4B, CTSA, CLTA | APP 3041/4885CYP2D6 1495/4885CHRM2 2645/4885 |
| US-20080051323-A1 | Chloroquine drug compositions and methods for their synthesis | CHMP4B, CTSA, CLTA | APP 2842/4885CYP2D6 1583/4885CHRM2 2827/4885 |
| US-20060040879-A1 | Chloroquine coupled nucleic acids and methods for their synthesis | TLR9, TLR3, EXOSC5 | APP 3286/4885CYP2D6 2234/4885CHRM2 3882/4885 |
| US-20240132611-A1 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | TFRC, FOLR1, CD47 | APP 3009/4885CYP2D6 2500/4885CHRM2 4057/4885 |
| US-20240132610-A1 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MYOF, MTPN, PYGM | APP 3618/4885CYP2D6 4806/4885CHRM2 3349/4885 |
| US-12006499-B2 | Una amidites and uses thereof | NCL, PNP, NASP | APP 1077/4885CYP2D6 3627/4885CHRM2 2890/4885 |
| US-20240228646-A9 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF | TFRC, FOLR1, CD47 | APP 3009/4885CYP2D6 2500/4885CHRM2 4057/4885 |
| US-11999955-B2 | Compositions and methods of treating facioscapulohumeral muscular dystrophy | MTPN, MYOF, CPT1B | APP 3444/4885CYP2D6 4754/4885CHRM2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.